Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma (STEREOPAC)

• ClinicalTrials.gov Identifier: NCT05083247
• Recruitment Status: Recruiting
• First Posted: October 19, 2021
• Last Update Posted: May 23, 2023
• Sponsor: Erasme University Hospital
• Collaborators: Jules Bordet Institute; Belgian Group of Digestive Oncology; University Hospital St Luc, Brussels
• Information provided by (Responsible Party): Erasme University Hospital

Study Description

Brief Summary:

Surgical resection is the only potentially curative treatment for patients with pancreatic cancer with the aim of curative R0 resection and related improvement of survival. As a standard, surgery is usually followed by adjuvant therapy that improves survival but neoadjuvant therapy (NAT) is a rapidly emerging concept that needs to be explored and validated in terms of therapeutic options in borderline resectable pancreatic tumors. In this setting, preoperative FFX seems to be feasible and can be prolonged by radiation therapy. However, the exact and best therapeutic sequence is not yet known and the additional role of adding isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT) to chemotherapy requires validation in randomised trials. We propose to evaluate the impact and efficacy of adding iHD-SBRT to preoperative neoadjuvant mFFX or Gem-NabP in patients with borderline resectable pancreatic adenocarcinoma.

Condition or disease	Intervention/treatment	Phase
Pancreatic Neoplasm; Pancreatic Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma	Drug: mFOLFIRINOX or Gemcitabine nab-paclitaxel; Radiation: Isotoxic High-Dose (iHD)-SBRT; Procedure: Surgery	Phase 2

Detailed Description:

STEREOPAC is an multicenter, academic, prospective, randomised comparative, interventional study.

Patients receive 4 cycles of mFOLFIRINOX (or Gem-Nab-P)*. A full restaging (clinical, morphologic imaging, vascular involvement, biologics, CA 19.9) is performed. Non-progressive patients will be randomised (1:1) to

ARM A for receiving 4 additional cycles of chemo followed by surgery.

or to

ARM B for receiving 5th and 6th cycles of chemo then iHD-SBRT followed by a 7th (and optional 8th cycle) followed by surgery.

*: in case of CI or intolerance to mFFX, Gem-Nab-P regimen can be chosen or shifted to for 6 doses, then restaging, and then 3 doses followed by SBRT or 6 doses and immediate surgery)

Adjuvant chemotherapy administration is indicated unless the patient's condition precludes it.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 256 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: comparative randomised phase II
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Preoperative Treatment With mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for Borderline Resectable Pancreatic Adenocarcinoma: a Randomised Phase II Study (STEREOPAC)
• Actual Study Start Date: March 24, 2023
• Estimated Primary Completion Date: December 31, 2027
• Estimated Study Completion Date: December 31, 2030

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Arm A; mFOLFIRINOX (oxaliplatin: 85 mg/m2, CPT-11: 165-180 mg/m2, folinic acid: 400mg/m2 and 5FU 2000-2400 mg/m2/46 h) regimen for 8 cycles every 2 weeks; or*Gemcitabine-Nab-P: gem: 1000 mg/m2 weekly 3 w/4; nab-P: 125 mg/m2 3 w/4 for 4 cycles in case of unfit for mFFX).	Drug: mFOLFIRINOX or Gemcitabine nab-paclitaxel; oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel; Other Name: mFFX or Gem/Nab-p; Procedure: Surgery; Surgery
Experimental: Arm B; mFOLFIRINOX for 6 cycles (or for 3 cycles Gemcitabine-Nab-P: gem: 1000 mg/m2 weekly 3 w/4; nab-P: 125 mg/m2 3 w/4 in case of unfit for mFFX) +Isotoxic high-dose SBRT: 5 x 7Gy with Simultaneous Integrated Boost (SIB) up to maximum 55Gy (= 1 week; starting ideally 2 weeks and maximum within 4 weeks after the end of chemotherapy)	Drug: mFOLFIRINOX or Gemcitabine nab-paclitaxel; oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel; Other Name: mFFX or Gem/Nab-p; Radiation: Isotoxic High-Dose (iHD)-SBRT; Radiation therapy; Procedure: Surgery; Surgery

Outcome Measures

Primary Outcome Measures :

1. Disease free survival [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 weeks ]
   Defined as time from randomisation to the first documentation of event where events considered are 1) disease progression, per RECIST, prior to surgery, 2) discovery of hepatic or peritoneal carcinomatosis during surgical exploration, 3) recurrent disease following R0-R1 surgery, or 4) death due to any cause.
2. R0 Resection rate [ Time Frame: up to 12 months ]
   Defined as the proportion of eligible randomised patients in whom a R0 resection was achieved during surgery after neoadjuvant treatment with FOLFIRINOX +/- iHD-SBRT. R0 resection indicates a microscopically margin-negative resection (>1 mm) from the inked margins (pancreatic transection, vascular and posterior circumferential resection margins).

Secondary Outcome Measures :

1. Resection rate [ Time Frame: up to 12 months ]
   defined as the percentage of eligible randomised patients that underwent a curative-intent resection
2. Pathologic complete/major response (pCR) [ Time Frame: up to 12 months ]
   Defined as the proportion of patients in whom a pCR or a major (<10% of residual tumour cells) was confirmed by histopathologic review of the surgical specimen.
3. Complete feasibility of the therapeutic sequence [ Time Frame: up to 12 months ]
   Defined as the proportion of patient who performed completely the neoadjuvant therapeutic sequence with mFFX (or Gem-Nab-P) +/- iHD-SBRT until surgery (abdominal exploration with or without pancreatectomy). The therapeutic sequence will not be considered as feasible if less than 60% of patients do not complete it until surgery.
4. Overall survival (OS) [ Time Frame: Defined as the time interval between randomisation and death, assessed up to 60 months ]
   Defined as the time interval between randomisation and death. 95% confidence interval will be estimated based on standard method.
5. Locoregional failure free interval (LFFI) [ Time Frame: defined as the time interval between the randomisation and the 1st documented date of locoregional failure, assessed up to 60 months ]
   defined as the time interval between the randomisation and the date of locoregional failure. A locoregional failure is any progressive or recurrent pancreatic cancer in the original tumour location or the N1-2 lymph node areas
6. Distant metastases free interval (DMFI) [ Time Frame: defined as the period of time without distant metastasis after randomisation, assessed up to 60 months ]
   defined as the period of time without distant metastasis after randomisation.
7. Toxicity, Incidence of adverse events [ Time Frame: up to 24 months ]
   assessed per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and the Patient-Reported Outcomes version of the CTCAE
8. Postoperative complications [ Time Frame: up to 12 months ]
   defined according to the Clavien-Dindo classification and definitions of post-pancreatic surgery complications (pancreatic fistula, delayed gastric emptying and bleeding) by the International study group on Pancreatic Surgery.
9. Quality of life (QoL) assessment - General [ Time Frame: up to 24 months ]
   assessed per EORTC General Quality of life of Cancer patient questionnaire QLQ-C30 version 3.0 (minimum value: 30 - maximum value: 126; higher score associated with worse QoL outcome).
10. Quality of life (QoL) assessment - Pancreatic cancer [ Time Frame: up to 24 months ]
    assessed per EORTC Quality of life of Pancreatic Cancer patient questionnaire QLQ-PAN26 (minimum value: 26 - maximum value: 104; higher score associated with worse QoL outcome).
11. Quality of life (QoL) assessment - Depression [ Time Frame: up to 24 months ]
    assessed per the depression test : Patient Health Questionnaire-9 (PHQ-9; minimum value: 0 - maximum value: 27; higher score associated with worse QoL outcome)
12. Technical and quality success rate of EUS-delivered fiducials. [ Time Frame: up to 12 months ]
    The technical success is defined as at least one marker presumed to be inside the tumour at the end of the EUS procedure. The quality success is defined as a score equal or higher than 6/12 points based on the 5 items quality score defined in [Figueiredo M, Bouchart C et al 2021].

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

• Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinated process or body or tail. Diagnosis should be verified by local pathologist
• cTNM stage: T1-4N0-2M0
• Confirmation of clinical and radiographic stage as borderline resectable (CT scan and/or MRI scan with contrast according to the NCCN criteria) by a multidisciplinary board, composed by a dedicated oncological surgeon, radiologist and GI oncologist)
• Age > 18 years old
• No prior chemotherapy or radiation for pancreatic cancer
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• No grade ≥ 2 neuropathy
• Laboratory parameters as follows:
• Absolute neutrophil count (ANC) ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 9 g/dL
• Creatinine ≤ 1.5 x upper limit of normal (ULN) or estimated GFR >45 mL/min
• Bilirubin ≤ 1.5 x ULN, including after adequate biliary stenting with metal stent (ideally 4 cm length)
• Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 2.5x ULN
• CA 19.9 < 2500 kU/l (baseline, prior to any therapy and absence of cholestasis)

Exclusion Criteria:

• Evidence of extrapancreatic disease on diagnostic imaging (CT, MRI or PET scan), histologically proven or at laparoscopy, including distal nodal involvement beyond the peripancreatic tissues (including non-regional lymph node involvement, ie: proven involvement of precaval lumbar lymphadenopathy(ies) and/or distant metastases
• Locally advanced disease as defined by the NCCN criteria (version 2.2021) ie > 180° arterial encasement (SMA and CA) unreconstructible venous encasement (SMV/PV) due to tumor involvement or occlusion of a long segment.
• CA 19.9 > 2500 kU/l (baseline and absence of cholestasis)
• Contraindication of surgery (general)
• Contraindications to receive FFX or gemcitabine-nab-Paclitaxel
• History of radiotherapy of the upper abdomen
• Prior treatment with oxaliplatin, irinotecan, fluoruouracil or capecitabin
• Patient < 18 years old
• Major surgery within 4 weeks of study entry
• Uncontrolled pre-existing disease including, but not limited to: active infection, symptomatic congestive heart failure, unstable angina, social / psychiatric disorder that would limit compliance to treatment and good understanding of the informed consent form
• Other concurrent anticancer therapies
• Existence of another active neoplasia other than basal cell carcinoma of the skin, cervical carcinoma in situ or non-metastatic prostate cancer. Patients who have a history of neoplasia must have been in remission for more than 5 years to be included in the protocol
• Pregnant or breastfeeding women; for women of childbearing potential only, a negative pregnancy test done < 7 days prior to registration is required. Using of reliable contraception for at least 1 month before treatment is mandatory
• Chronic concomitant treatment with strong inhibitors of cytochrome p450, family 3, subfamily a, polypeptide 4 gene (CYP3A4) is not allowed on this study; patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study

Additional exclusion criteria before randomisation:

• Progressive disease (RECIST or PETCT, including non locoregional nodal involvement and increase of CA 19.9 by 20%) after receiving 4 cycles of FFX (or G/NP), including shift chemotherapy in case of early progression.
• CA 19.9 > 1000 kU/l after neoadjuvant therapy.
• Presence of unmanageable toxicity during the first part of neoadjuvant chemotherapy (first 4 cycles or 6 doses of FFX or G/NP, respectively.
• Pancreatic tumour > 7.0 cm in greatest axial dimension at the time of randomization
• Massive invasion of the stomach or intestines and/or direct intestinal invasion of the mucosae visible at ultrasoundendoscopy
• Active gastric or duodenal ulcer disease at the time of randomization. Tolerated in case of antecedent without active ulcer (confirmation by endoscopy before iHD-SBRT)

Contacts and Locations

Contacts

Contact: Jean-Luc Van Laethem, MD PhD; 003225553714; jl.vanlaethem@erasme.ulb.ac.be

Contact: Mia Persoons; 003225553016; mia.persoons@erasme.ulb.ac.be

Locations

Belgium

Uza Antwerp; Recruiting

Antwerp, Belgium, 2650

Contact: Timon Vandamme, MD Timon.vandamme@uza.be

Hopital Erasme, HUB; Recruiting

Brussels, Belgium, 1070

Contact: Jean-Luc Van Laethem, MD 003225553714 jl.vanlaethem@erasme.ulb.ac.be

Contact: Mia Persoons 003225553016 mia.persoons@erasme.ulb.ac.be

Jules Bordet Institute, HUB; Recruiting

Brussels, Belgium, 1070

Contact: Christelle Bouchart, MD +32 2 541 38 00 christelle.bouchart@bordet.be

CHIREC; Recruiting

Brussel, Belgium, 1160

Contact: Francesco Puleo, MD francesco_puleo@hotmail.com

Cliniques Universitaires St luc; Recruiting

Brussel, Belgium, 1200

Contact: Ivan Borbath, MD ivan.borbath@uclouvain.be

UZ Gent; Not yet recruiting

Gent, Belgium, 9000

Contact: Karen Geboes, MD karen.Geboes@uzgent.be

AZ Groeninge; Recruiting

Kortrijk, Belgium, 8500

Contact: Philippe Vergauwe, MD philippe.vergauwe@azgroeninge.be

Pôle Hospitalier Jolimont; Recruiting

La Louvière, Belgium, 7100

Contact: Alexandre Dermine, MD alexandre.dermine@jolimont.be

Clinique Chc Montlégia; Recruiting

Liège, Belgium, 4000

Contact: Ghislain Houbiers, MD ghislain.houbiers@chc.be

CHU Ambroise Paré; Recruiting

Mons, Belgium, 7000

Contact: Marie Diaz, MD marie.diaz@hap.be

Sponsors and Collaborators

Erasme University Hospital

Jules Bordet Institute

Belgian Group of Digestive Oncology

University Hospital St Luc, Brussels

Investigators

• Study Chair: Jean-Luc Van Laethem, MD; Erasme Hospital, ULB
• Principal Investigator: Christelle Bouchart, MD; Jules Bordet Institute

More Information

Publications:

Figueiredo M, Bouchart C, Moretti L, Mans L, Engelholm JL, Bali MA, Van Laethem JL, Eisendrath P. EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score. Endosc Int Open. 2021 Feb;9(2):E253-E257. doi: 10.1055/a-1324-2892. Epub 2021 Feb 3.

Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gokburun Y, De Grez T, Mans L, Hendlisz A, Bali MA, Eisendrath P, Van Gestel D, Hein M, Moretti L, Van Laethem JL. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Ther Adv Med Oncol. 2021 Oct 19;13:17588359211045860. doi: 10.1177/17588359211045860. eCollection 2021.

Manderlier M, Navez J, Hein M, Engelholm JL, Closset J, Bali MA, Van Gestel D, Moretti L, Van Laethem JL, Bouchart C. Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation. Cancers (Basel). 2022 Nov 22;14(23):5730. doi: 10.3390/cancers14235730.

• Responsible Party: Erasme University Hospital
• ClinicalTrials.gov Identifier: NCT05083247
• Other Study ID Numbers: ERA 001
• First Posted: October 19, 2021
• Last Update Posted: May 23, 2023
• Last Verified: March 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Erasme University Hospital:

borderline resectable pancreatic cancer; neoadjuvant therapy; stereotactic body radiation therapy; chemotherapy

Additional relevant MeSH terms:

Adenocarcinoma; Pancreatic Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Paclitaxel; Gemcitabine; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites